High-soluble CGA levels are associated with poor survival in bladder cancer

T. Szarvas, B. Jardin-Watelet, N. Bourgoin, M. J. Hoffmann, P. Nyirády, C. Oláh, T. Széll, A. Csizmarik, B. Hadaschik, H. Reis

Research output: Contribution to journalArticle

Abstract

Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer BC. Chromogranin A CGA is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA sCGA concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma RCC. sCGA concentrations were analyzed in the following cohorts: 1 BC training set n = 188, 2 BC validation set n = 125, 3 RCC patients n = 77, 4 healthy controls n = 97. CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were signific antly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training P < 0.001, P = 0.002 and validation set P = 0.009, P = 0.017. sCGA levels were inversely correlated with glomerulus filtrating rate GFR and linearly correlated wi th creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR , the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities.

Original languageEnglish
Pages (from-to)625-633
Number of pages9
JournalEndocrine Connections
Volume8
Issue number5
DOIs
Publication statusPublished - May 2019

Fingerprint

Urinary Bladder Neoplasms
Survival
Comorbidity
Chromogranin A
Neuroendocrine Tumors
Renal Cell Carcinoma
Urea
Creatinine
Biomarkers
Immunohistochemistry
Kidney
Muscles
Serum

Keywords

  • Bladder cancer
  • CGA
  • Chromogranin A
  • Neuroendocrine
  • Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Szarvas, T., Jardin-Watelet, B., Bourgoin, N., Hoffmann, M. J., Nyirády, P., Oláh, C., ... Reis, H. (2019). High-soluble CGA levels are associated with poor survival in bladder cancer. Endocrine Connections, 8(5), 625-633. https://doi.org/10.1530/EC-19-0068

High-soluble CGA levels are associated with poor survival in bladder cancer. / Szarvas, T.; Jardin-Watelet, B.; Bourgoin, N.; Hoffmann, M. J.; Nyirády, P.; Oláh, C.; Széll, T.; Csizmarik, A.; Hadaschik, B.; Reis, H.

In: Endocrine Connections, Vol. 8, No. 5, 05.2019, p. 625-633.

Research output: Contribution to journalArticle

Szarvas, T, Jardin-Watelet, B, Bourgoin, N, Hoffmann, MJ, Nyirády, P, Oláh, C, Széll, T, Csizmarik, A, Hadaschik, B & Reis, H 2019, 'High-soluble CGA levels are associated with poor survival in bladder cancer', Endocrine Connections, vol. 8, no. 5, pp. 625-633. https://doi.org/10.1530/EC-19-0068
Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C et al. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocrine Connections. 2019 May;8(5):625-633. https://doi.org/10.1530/EC-19-0068
Szarvas, T. ; Jardin-Watelet, B. ; Bourgoin, N. ; Hoffmann, M. J. ; Nyirády, P. ; Oláh, C. ; Széll, T. ; Csizmarik, A. ; Hadaschik, B. ; Reis, H. / High-soluble CGA levels are associated with poor survival in bladder cancer. In: Endocrine Connections. 2019 ; Vol. 8, No. 5. pp. 625-633.
@article{e42512b90f47462489fd5a570a17c702,
title = "High-soluble CGA levels are associated with poor survival in bladder cancer",
abstract = "Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer BC. Chromogranin A CGA is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA sCGA concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma RCC. sCGA concentrations were analyzed in the following cohorts: 1 BC training set n = 188, 2 BC validation set n = 125, 3 RCC patients n = 77, 4 healthy controls n = 97. CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were signific antly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training P < 0.001, P = 0.002 and validation set P = 0.009, P = 0.017. sCGA levels were inversely correlated with glomerulus filtrating rate GFR and linearly correlated wi th creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR , the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities.",
keywords = "Bladder cancer, CGA, Chromogranin A, Neuroendocrine, Serum",
author = "T. Szarvas and B. Jardin-Watelet and N. Bourgoin and Hoffmann, {M. J.} and P. Nyir{\'a}dy and C. Ol{\'a}h and T. Sz{\'e}ll and A. Csizmarik and B. Hadaschik and H. Reis",
year = "2019",
month = "5",
doi = "10.1530/EC-19-0068",
language = "English",
volume = "8",
pages = "625--633",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",
number = "5",

}

TY - JOUR

T1 - High-soluble CGA levels are associated with poor survival in bladder cancer

AU - Szarvas, T.

AU - Jardin-Watelet, B.

AU - Bourgoin, N.

AU - Hoffmann, M. J.

AU - Nyirády, P.

AU - Oláh, C.

AU - Széll, T.

AU - Csizmarik, A.

AU - Hadaschik, B.

AU - Reis, H.

PY - 2019/5

Y1 - 2019/5

N2 - Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer BC. Chromogranin A CGA is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA sCGA concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma RCC. sCGA concentrations were analyzed in the following cohorts: 1 BC training set n = 188, 2 BC validation set n = 125, 3 RCC patients n = 77, 4 healthy controls n = 97. CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were signific antly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training P < 0.001, P = 0.002 and validation set P = 0.009, P = 0.017. sCGA levels were inversely correlated with glomerulus filtrating rate GFR and linearly correlated wi th creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR , the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities.

AB - Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer BC. Chromogranin A CGA is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA sCGA concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma RCC. sCGA concentrations were analyzed in the following cohorts: 1 BC training set n = 188, 2 BC validation set n = 125, 3 RCC patients n = 77, 4 healthy controls n = 97. CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were signific antly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training P < 0.001, P = 0.002 and validation set P = 0.009, P = 0.017. sCGA levels were inversely correlated with glomerulus filtrating rate GFR and linearly correlated wi th creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR , the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities.

KW - Bladder cancer

KW - CGA

KW - Chromogranin A

KW - Neuroendocrine

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=85073277189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073277189&partnerID=8YFLogxK

U2 - 10.1530/EC-19-0068

DO - 10.1530/EC-19-0068

M3 - Article

AN - SCOPUS:85073277189

VL - 8

SP - 625

EP - 633

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 5

ER -